Sermorelin vs Tesamorelin
Verdict: Both are GHRH analogs, but they live in different evidence classes. Tesamorelin is FDA-approved (Egrifta), with human trials showing real visceral-fat reduction at 2 mg daily — the strongest clinical evidence of any GH-axis peptide. Sermorelin is the affordable clinic staple: decades of prescribing history, flexible dosing, a fraction of the cost, but no comparable outcome trials. If targeting stubborn visceral/abdominal fat with maximum evidence, tesamorelin earns its price. For general GH-axis support on a budget, sermorelin remains the entry point.
Side by side
| Sermorelin | Tesamorelin | |
|---|---|---|
| Typical dose | 200 mcg–500 mcg | 1 mg–2 mg |
| Frequency | nightly before bed | daily |
| Administration | subcutaneous injection | subcutaneous injection |
| Common vials | 2 mg, 5 mg, 10 mg | 5 mg, 10 mg |
| Typical mix | 5 mg + 2 ml water | 5 mg + 2 ml water |
| Units for typical dose | 12 units (300 mcg) | 80 units (2 mg) |
The evidence gap
Tesamorelin's approval trials measured actual body-composition outcomes: ~15-18% visceral adipose reduction over 26 weeks in its studied population. Sermorelin's evidence is mostly about mechanism — it reliably raises GH and IGF-1 — with outcomes inferred rather than trial-proven. This distinction, not potency folklore, is the real difference.
Cost vs dose economics
Tesamorelin's effective dose is high (1–2 mg daily), so despite similar per-vial prices its monthly cost runs several times sermorelin's 200–500 mcg nightly. Budget-constrained protocols sometimes run tesamorelin at reduced doses, but the trial evidence is at 2 mg — below that, you're extrapolating.
Same family, same pairing logic
As GHRH analogs, both slot into the 'amplifier' role and pair naturally with ipamorelin for the dual-receptor synergy. Tesamorelin + ipamorelin has become the premium clinic stack; sermorelin + ipamorelin is the classic accessible version.
Can you stack them?
Either pairs with a secretagogue (ipamorelin). Running both GHRH analogs together adds cost, not benefit — one amplifier per protocol.
More comparisons
Educational comparison based on commonly published research protocols — not medical advice or an endorsement of any compound.